Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage
Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage
1. To evaluate the effectiveness of Huperzine A injection in the treatment of brain injury
 in patients with hypertensive cerebral hemorrhage；

 2. To evaluate the safety of Huperzine A injection in the treatment of brain injury in
 patients with hypertensive cerebral hemorrhage。
A randomized, controlled, single-center, exploratory clinical research method was used. In
 the treatment plan, the experimental group used basic treatment + Huperzine A, and the
 control group only used basic treatment, with a total of 20 cases. To evaluate the
 effectiveness and safety of Huperzine A injection in the treatment of brain injury in
 patients with hypertensive cerebral hemorrhage.
Inclusion Criteria:

 1. Aged from 18 to 75 years old(including 18 and 75 years old), males or females;

 2. First onset, clinical diagnosis of hypertensive intracerebral hemorrhage, and CT
 confirmed that the amount of hemorrhage is between 15ml-50ml, the bleeding site is the
 basal ganglia, the bleeding has not penetrated into the lateral ventricle, and
 non-surgical patients；

 3. Those with obvious neurological dysfunction after the onset, 5≤GCS≤15 or NIHSS≥6；

 4. Admission within 72 hours after the onset of the disease, and no significant
 enlargement of the hematoma within 24 hours after admission (hematoma enlargement ≤
 5ml)；

 5. The patient/family knows and signs the informed consent form voluntarily.

 Exclusion Criteria:

 1. Cerebral hemorrhage caused by cerebral aneurysm, brain tumor, brain trauma, cerebral
 parasitic disease, cerebrovascular malformation, abnormal blood vessel network at the
 base of the brain, cerebral arteritis, blood disease, metabolic disorder and other
 diseases confirmed by examination;

 2. Patients with enlarged hematoma found within 24 hours after admission (the volume of
 enlarged hematoma> 5ml);

 3. Patients with simple transient ischemic attack, lacunar infarction, subarachnoid
 hemorrhage and ischemic cerebral infarction;

 4. Patients who use anticoagulant drugs for a long time;

 5. Patients with platelet count <100,000, INR>1.4 at admission and abnormal blood
 coagulation function;

 6. The measured value of homocysteine at admission is higher than 15μmol/L;

 7. Patients who need surgical treatment (including ventricular drainage);

 8. Patients with severe primary diseases such as cardiovascular, liver (ALT or AST>1.5
 times the upper limit of normal), kidneys (BUN>1.5 times the upper limit of normal and
 Cr>upper limit of normal), endocrine system and hematopoietic system;

 9. Those who are allergic to protein and test drugs;

 10. People who are dependent on drugs or alcohol;

 11. Intended pregnancy or women of childbearing age with positive pregnancy test and
 lactating women;

 12. Participated in other clinical trials within the past 3 months;

 13. Patients considered by the investigator to be inappropriate to participate in clinical
 trials.